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tastasis	 through	 blood	 and	 lymphatic	 vessels.	We	 undertook	 a	 systematic	 review	
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1  | INTRODUC TION
Tongue	squamous	cell	carcinoma	(TSCC)	is	one	of	the	most	com‐
mon	 types	 of	 head	 and	 neck	 squamous	 cell	 carcinoma	 (HNSCC)	




tool	 in	 predicting	 the	 treatment	 and	 survival	 outcomes	of	 TSCC	
patients.3	The	TNM	classification	is	currently	the	mainstay	of	clin‐














to	 regional	 lymph	 nodes	 and	 distant	 tissues.10	 In	 fact,	 some	 can‐






cular	parameters	 is	often	 facilitated	by	 the	use	of	well‐established	
immunohistochemical	antibodies	(Abs).	These	Abs	include	a	variety	
of	blood	vessel	markers,	such	as	CD34,	CD31,	CD105	(endoglin),	and	
FVIII	 in	 addition	 to	markers	 for	 lymphatic	 vessels,	 such	 as	 D2‐40	
(podoplanin)	and	LYVE‐1.
Assessment	of	prognostic	parameters	 at	 the	 time	of	diagnosis	
is	 essential	 for	 proper	 risk	 stratification	 of	 cancer	 patients.16 To 
the	best	of	our	knowledge,	there	are	currently	no	biomarkers	that	
reliably	 correlate	with	 the	 prognosis	 and	 therapeutic	 response	 in	
TSCC	 patients.	 Several	 studies	 have	 investigated	 the	 potential	 of	
the	 tumor	 vasculature	 as	 a	 prognosticator	 in	 TSCC.	 Therefore,	 in	
this	study	we	sought	to	systematically	review	the	current	evidence	




This	 review	 study	was	 registered	 at	 the	 international	 prospective	
register	 of	 systematic	 reviews	 PROSPERO	 (https	://www.crd.york.
ac.uk/prosp	ero/)	with	the	registration	number	CRD42019115141.
2.2 | Search strategy




“blood	 vessel”	 OR	 “lymphangiogenesis”	 OR	 “lymphatic	 vessel”	 OR	








The	 results	 obtained	 with	 these	 search	 terms	 were	 gathered	
together	 in	RefWorks.	The	article	 search	was	undertaken	with	no	
time/language	restrictions	on	28	June	2018	and	therefore	articles	












The	 following	 information	was	extracted	 from	each	 study:	 (i)	 basic	
article	information,	including	first	author,	publication	year,	study	pe‐
riod,	 and	 follow‐up	duration;	 (ii)	 patient	and	 tumor	 information,	 in‐
cluding	the	number	and	location	of	patients,	mean	age,	gender,	tumor	
site	and	size,	disease	stage,	number	of	patients	who	underwent	im‐
munohistochemical	 staining	 and	 the	 number	with	 positive	 staining	
results,	name	and	source	of	the	Ab,	Ab	dilution,	and	sample	preser‐
vation	(paraffin‐embedded	or	frozen);	(iii)	survival	analysis,	including	





2.4 | Quality and risk of bias assessment
We	 assessed	 the	 reporting	 quality	 of	 the	 eligible	 studies	 accord‐
ing	 to	 the	 REMARK	 guidelines,	 a	 20‐item	 checklist	 aimed	 at	 en‐
suring	 the	 quality	 and	 reproducibility	 of	 the	 reported	 data.18 The 
selected	and	applied	REMARK	guidelines	of	the	eligible	studies	are	
listed	in	Table	S2.	For	the	risk	of	bias,	two	authors	(R.A.	and	M.K.)	
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answered	 10	 questions	 for	 each	 study	 using	 MAStARI.	 Answers	







We	 found	 a	 total	 of	 515	 articles	 from	 3	 electronic	 databases	
(332	 from	 Ovid	 Medline,	 142	 from	 Scopus,	 and	 41	 from	 the	
Cochrane	 Library)	 and	 1	 from	 a	 previous	 search.	 After	 screen‐













3.2 | Risk of bias results
Based	 on	 the	 MAStARI	 evaluation	 tool,	 the	 risk	 of	 bias	 in	 the	
included	articles	was	either	 low	 (n	=	9)	or	moderate	 (n	=	4).	The	
risk	of	bias	for	each	study	and	the	applied	questions	are	shown	in	
Table	S3.
3.3 | Preoperative treatments of the 
studied cohorts
As	 the	 preoperative	 treatment	 could	 impact	 the	 expression	 of	
MVD/LVD	 in	 the	 studied	 patient	 samples,	 we	 screened	 the	 in‐
cluded	 reports	 to	 extract	 any	 relevant	 data.	 The	 samples	 were	
not	subjected	to	any	sort	of	preoperative	treatments	in	a	total	of	
7	 studies.19‐22,25,29,31	 In	 one	 study	 from	 India,	 the	 patients	 were	
primarily	 treated	 by	 either	 surgery	 or	 radiotherapy.26	 Some	 of	
the	patients	who	underwent	surgery	were	also	given	adjuvant	ra‐
diotherapy,	 chemotherapy,	 or	 radiotherapy	 and	 chemotherapy.26 
However,	this	information	was	either	missing	or	not	clearly	stated	
in	the	other	5	studies.23,24,27,28,30
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3.4 | Microvessel density markers as 
prognosticators in TSCC












et	 al,23	 the	CD34‐expressing	vessel	 count	 (VC)	was	not	 associated	




3.4.2 | Prognostic value of CD31 and CD105
We	found	only	one	study	that	used	CD31	to	correlate	MVD	and	the	
prognosis	 of	 43	 patients	 with	 TSCC.24	 In	 this	 small	 cohort	 study,	
Cox	regression	analysis	did	not	 indicate	tumor	vascularization	as	a	
prognostic	 factor	of	 survival	 (P = .59).	Chuang	et	 al25	 investigated	
the	expression	of	CD105	 in	94	TSCC	patients	 and	 found	 that	 the	
cumulative	5‐year	DFS	rates	of	patients	with	low	CD105	expression	
were	significantly	higher	than	those	with	high	expression	(P < .001).	
Moreover,	 Cox	 regression	 analysis	 showed	 that	 the	 expression	 of	
CD105	was	an	independent	factor	from	other	variables	for	survival	
(relative	 risk	8.0;	 95%	CI,	 2.525‐25.839;	P < .001).	Characteristics	
of	the	studies	regarding	these	2	markers	are	summarized	in	Table	2.










3.5 | Lymphatic vessel density markers as 
prognosticators in TSCC
3.5.1 | Prognostic value of D2‐40
Al‐Shareef	 et	 al28	 revealed	 a	 strong	 correlation	 between	 D2‐40	





metastasis.	 In	 the	61	cases	 analyzed	by	Seppälä	et	 al,30	 the	mean	
LVD	did	not	 influence	patient	 survival.	However,	 the	 relative	den‐
sity	 of	 lymphatic	 vessels	 (RDLV)	was	 significantly	 associated	with	




3.5.2 | Prognostic value of LYVE‐1
Ding	et	al31	evaluated	the	prognostic	value	of	LYVE‐1	in	50	cases	and	








metastasis.14	Metastasis	 is	 estimated	 to	 be	 responsible	 for	 approxi‐
mately	90%	of	 cancer‐associated	deaths.32	TSCC	 is	one	of	 the	most	















could	 therefore	 become	 an	 integral	 part	 of	 a	more	 reliable	 staging	
system.34‐36	 Moreover,	 the	 use	 of	 CD34	 as	 an	 angiogenic	 marker	
was	 superior	 to	other	markers	as	 it	 yielded	better	 results	with	 less	



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































survival	 by	 multivariate	 analysis	 according	 to	 the	 Cox	 regression	
model,25	prognostic	value	was	not	found	when	CD31	was	assessed.	











significantly	 associated	 with	 poor	 OS	 in	 TSCC	 patients.30	 However,	
these	results	should	be	confirmed	with	studies	in	a	larger	patient	cohort.













In	 conclusion,	 although	 the	 evidence	 reported	 in	 this	 review	




practice.	This	 is	due	to	several	 factors,	such	as	 the	small	patient	
cohorts	of	the	studies,	different	assessment	criteria	used	for	MVD	
and	LVD	markers,	the	heterogeneity	of	the	study	samples	(mixing	
either	 base	 of	 the	 tongue	 “posterior	 1/3”,	 oral	 tongue	 “anterior	
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